Table 1.
Patient characteristics
| Variables | Total patient (N=119) |
|---|---|
| Median patient’s age at transplant, years (range) | 46 (21~69) |
| Median donor’s age, years (range) | 35 (14~63) |
| Gender of patient, male (N, %) | 61 (51.3) |
| Gender of donor, male (N, %) | 83 (69.7) |
| Female to male transplant (N, %) | 19 (16.0) |
| Not available to evaluate (heterogeneous sex in double cord donor) (N, %) | 5 (4.2) |
| Diagnosis | |
| Acute myeloid leukemia (N, %) | 74 (62.2) |
| Acute lymphoblastic leukemia (N, %) | 44 (37.8) |
| Mixed phenotype acute leukemia (N, %) | 1 (0.8) |
| Donor type | |
| HLA-well matched sibling (N, %) | 48 (40.3) |
| HLA-well matched unrelated (N, %) | 37 (31.1) |
| HLA-partial matched unrelated (N, %) | 3 (2.5) |
| Haploidentical related (N, %) | 23 (19.3) |
| Double cord (N, %) | 8 (7.6) |
| Donor source | |
| Peripheral blood | 93 (78.2) |
| Bone marrow | 18 (15.1) |
| Cord blood | 8 (6.7) |
| Comorbidity (HCT-CI*) | |
| Low to intermediate (score <3) (N, %) | 81 (68.1) |
| High (score ≥3) (N, %) | 38 (31.9) |
| Conditioning intensity | |
| Myeloablative conditioning (N, %) | 84 (70.6) |
| Total body irradiation 1320 cGy+cyclophosphamide 120 mg/kg | 57 (47.9) |
| Total body irradiation 1200 cGy+fludarabine 150 mg/m2+cytaratbine 9.0 mg/m2 | 7 (5.9) |
| Fludarabine 150 mg/m2+busulfex 9.6 mg/kg | 14 (11.8) |
| Busulfex (12.8 mg/kg)+cyclophosphamide 120 mg/kg | 6 (5.0) |
| Reduced intensity conditioning (N, %) | 35 (29.4) |
| Total body irradiation 800 cGy+fludarabine 150 mg/m2+busulfex 6.4 mg/kg | 19 (16.0) |
| Total body irradiation 800 cGy+fludarabine 150 mg/m2+cytaratbine 9.0 mg/m2 | 1 (0.8) |
| Total body irradiation 400 cGy+fludarabine 150 mg/m2+busulfex 6.4 mg/kg | 12 (10.1) |
| Fludarabine 150 mg/m2+busulfex 6.4 mg/kg | 3 (2.5) |
| Antithymocyte globulin | |
| None | 42 (35.3) |
| 1.25~2.5 mg/kg | 46 (38.7) |
| 5.0~10.0 mg/kg | 31 (26.1) |
| Median infused donor CD34+Cells at HSCT, ×106/kg (range) | 5.7 (0.1~21.1) |
| Median infused donor CD3+Cells at HSCT, ×106/kg (range) | 339.9 (2.9~901.4) |
| Graft-versus-host disease prophylaxis | |
| Methotrexate+cyclosporine | 45 (37.8) |
| Methotrexate+tacrolimus | 66 (55.5) |
| Mycophenolate mofetil+tacrolimus | 8 (6.7) |
| Post-transplant immune cell population, median frequency, %/MNC (range) | |
| CD3+T cells, N=117 | 26.8 (0.218~88.3) |
| CD4+T cells, N=119 | 4.39 (0.002~54.0) |
| CD8+T cells, N=119 | 14.3 (0.107~56.7) |
| CD56+cells, N=117 | 4.757 (0.0~28.002) |
| Natural killer cells (CD3−CD56+), N=117 | 8.1 (0.0~62.0) |
| NKT-like cells (CD3+CD56+), N=117 | 2.63 (0.004~20.6) |
| Regulatory T cells (CD25+CD127low in CD3+CD4+cells), N=76 | 0.898 (0.0~22.996) |
| invariant NKT cells (iNKT cells, Vβ11+CD3+), N=117 | 0.061 (0.0~8.805) |
| NKG2D expression on NK cells, N=117 | 5.617 (0.025~40.906) |
| NKG2D expression on NKT-like cells, N=117 | 1.182 (0.0~11.921) |
| MAIT cells (CD8+CD161+Vα7.2+), N=119 | 0.429 (0.003~1.701) |
| G-MDSC (HLA-DR−LIN−CD11b+CD33+), N=119 | 0.258 (0.009~13.4) |
| M-MDSC (HLA-DR−CD14+), N=119 | 0.109 (0.004~4.325) |
HCT-CI: hematopoietic cell transplantation-comorbidity index, HSCT: hematopoietic stem cell transplantation, MNC: mononuclear cell, NKT: natural killer T cell, NKG2D: natural killer group 2, member D, MAIT: mucosal associated invariant T cell, MDSC: myeloid-derived suppressor cell.
*
HCT-CI was defined by Sorror et al. (21).